• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Kelly Jared claimed ownership of 73,900 shares (SEC Form 3)

    1/2/26 4:30:39 PM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ONCY alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Kelly Jared

    (Last) (First) (Middle)
    C/O ONCOLYTICS BIOTECH INC.
    4350 EXECUTIVE DRIVE, SUITE 325

    (Street)
    SAN DIEGO CA 92121

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    01/01/2026
    3. Issuer Name and Ticker or Trading Symbol
    ONCOLYTICS BIOTECH INC [ ONCY ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Executive Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Shares 73,900 D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (1) 06/11/2030 Common Shares 2,850,000 $0.57(2) D
    Stock Option (3) 08/15/2030 Common Shares 450,000 $1.08 D
    Stock Option (4) 12/15/2030 Common Shares 350,000 $0.99 D
    Explanation of Responses:
    1. The stock option vests in three equal annual installments beginning on June 11, 2026.
    2. The exercise price is listed in Canadian dollars.
    3. The stock option vests in three equal annual installments beginning on August 15, 2026.
    4. The stock option vests in three equal annual installments beginning on December 15, 2026.
    Remarks:
    Exhibit 24 - Power of Attorney.
    /s/ Kirk Look, Attorney-in-Fact 01/02/2026
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ONCY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ONCY

    DatePrice TargetRatingAnalyst
    8/13/2025$7.00Buy
    Lake Street
    10/6/2022$3.00Buy
    Maxim Group
    More analyst ratings

    $ONCY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment

    Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC., Jan. 28, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – As the global oncology clinical trials market surges toward a projected $25.61 billion valuation by 2035[1], a structural rotation is favoring 'registration-ready' platforms that demonstrate exceptional efficacy and pivotal-trial alignment with 2026's evolving FDA regulatory frameworks[2]. Investors are increasingly prioritizing late-stage and newly commercial companies poised for rapid maturation as sector fundamentals strengthen. This structural shift creates a window for Oncolytics Biotech Inc. (NASDAQ:ONCY), BioNTech (NASDAQ:BNTX), MAIA Biotechnology (NYSE-A: MAIA)

    1/28/26 9:15:00 AM ET
    $ACRV
    $BNTX
    $IBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks

    Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Jan. 27, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary – The global oncology therapy market is charging toward a massive $668 billion valuation by 2034, as a ruthless capital rotation finally rewards execution-ready platforms over the "hopes and dreams" of speculative discovery assets[1]. With the FDA's accelerated approval pathway delivering survival wins across 65% of solid tumor indications, the 2026 regulatory landscape is demanding a new breed of registration-directed study designs that prioritize raw objective response rates and durability[2]. This structural shift creates an asymmetric investment window for Oncolytic

    1/27/26 10:50:00 AM ET
    $CHRS
    $MRK
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    THE RESILIENCE DOCTRINE: 5 Assets Securing the 2026 Sovereign Stack

    VANCOUVER, British Columbia, Jan. 26, 2026 (GLOBE NEWSWIRE) --  Equity Insider Market Intelligence Brief – The global market has entered a cycle of defensive hardening. After a decade of aggressive speculation, the defining theme of 2026 is Resilience. Investors are realizing that the systems powering the modern world—from the energy grid to the human body—are dangerously fragile. The "Everything Bubble" ignored physical and biological reality. Now reality is repricing the market. Capital is rotating into the "Sovereign Stack": the critical minerals that cannot be substituted, the supply chains that must be domesticated, and the biological technologies that extend the lifespan of the w

    1/26/26 10:13:47 AM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Oncolytics Biotech with a new price target

    Lake Street initiated coverage of Oncolytics Biotech with a rating of Buy and set a new price target of $7.00

    8/13/25 8:42:12 AM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Oncolytics Biotech with a new price target

    Maxim Group initiated coverage of Oncolytics Biotech with a rating of Buy and set a new price target of $3.00

    10/6/22 9:22:17 AM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Oncolytics Biotech with a new price target

    H.C. Wainwright initiated coverage of Oncolytics Biotech with a rating of Buy and set a new price target of $15.00

    2/17/21 2:20:07 PM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Seizinger Bernd R. bought $103,770 worth of shares (100,000 units at $1.04), increasing direct ownership by 27% to 466,991 units (SEC Form 4)

    4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)

    1/20/26 4:30:18 PM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Kelly Jared claimed ownership of 73,900 shares (SEC Form 3)

    3 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)

    1/2/26 4:30:39 PM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Andrews Patricia S claimed ownership of 42,728 shares (SEC Form 3)

    3 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)

    1/2/26 4:30:41 PM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCY
    SEC Filings

    View All

    Oncolytics Biotech Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)

    1/15/26 4:21:34 PM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oncolytics Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)

    1/14/26 6:10:26 PM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oncolytics Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)

    1/12/26 4:05:33 PM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCY
    Financials

    Live finance-specific insights

    View All

    Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep

    Key opinion leader event and pancreatic cancer clinical data validate decision to engage with regulators on plans for a registration-enabling study New members of the management team bring expertise in progressing clinical programs and executing successful biotech transactions Translational data further elucidate pelareorep's mechanism of action and ability to prime the tumor microenvironment for treatment Commitment to limiting dilution evidenced by termination of At-the-Market and Equity Line of Credit facilities SAN DIEGO, Aug. 8, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareo

    8/8/25 9:05:00 AM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

    American Society of Clinical Oncology (ASCO) GI Symposium data underscores pelareorep's clinical benefit in anal and pancreatic cancers Pelareorep featured in Key Opinion Leader event on oncolytic immunotherapies in breast and pancreatic cancers Poster on pelareorep's stimulation of adaptive and innate immunity to be shared at ASCO Annual Meeting Conference call and webcast today at 4:30 p.m. ET to discuss Q1 results and clinical outlook SAN DIEGO, Calif. and CALGARY, AB, May 14, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today reported on highlights and financial results for the first qu

    5/14/25 4:01:00 PM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

    Conference call and webcast to take place on Wednesday, May 14, 2025, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB, May 6, 2025 Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Wednesday, May 14, 2025, at 4:30 p.m. ET to discuss a corporate update and financial results for the first quarter of 2025. Conference Call & Webcast Date: Wednesday, May 14, 2025Time: 4:30 p.m. ETDial In – North American Toll-Free: (888) 510-2154Dial In – Interna

    5/6/25 7:00:00 AM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCY
    Leadership Updates

    Live Leadership Updates

    View All

    The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

    VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by 2035 as the industry moves toward the coordinated activation of the immune system[1]. This surge is being accelerated by the $69.16 billion genomics revolution, which is now integrating advanced profiling into every oncology workflow to pick winning treatments[2]. This strategic push for registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), OS Therapies (NYSE-A: OSTX), BioNTech SE (NASDAQ:BNTX),

    1/14/26 10:39:59 AM ET
    $BNTX
    $CMPX
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics

    SAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the appointment of John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics. These appointments are expected to enhance the Company's operational, clinical, and regulatory capabilities as Oncolytics advances registration-directed development programs in pancreatic, colorectal, and anal cancers. Mr. McAdory will oversee clinical development execution, operational strategy, and regulatory readiness across the Company's portfolio. He br

    1/14/26 9:00:00 AM ET
    $CGON
    $ONCY
    $TAK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O'Reilly, Dr. Neil Segal, and Dr. Van Morris

    New members bring deep experience in pancreatic, colorectal, and anal cancers to guide pelareorep's development as a platform immunotherapy across GI tumors Company continues to strengthen its clinical and strategic foundation to advance registration-enabling studies in high-value indications Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the expansion of its gastrointestinal ("GI") Tumor Scientific Advisory Board ("SAB") with the appointment of Dr. Eileen O'Reilly, Dr. Neil Segal, and Dr. Van Morris, three globally recognized experts in gastrointestinal oncology. The GI SAB was recent

    1/7/26 9:00:00 AM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Seizinger Bernd R. bought $103,770 worth of shares (100,000 units at $1.04), increasing direct ownership by 27% to 466,991 units (SEC Form 4)

    4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)

    1/20/26 4:30:18 PM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care